Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuranolone PK and Safety in Adolescents with MDD
NCT05655507Phase 1Completed
- Sponsor
- Biogen
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zuranolone in major depressive disorder (MDD), sponsored by Biogen. Primary endpoint: Plasma Concentrations of Zuranolone at Day 15. Started Apr 2023; status: completed.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05655507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05655507.